文献速递呼吸道感染呼吸危重症与机械通气

经鼻高流量氧疗与常规氧疗在COVID-19肺炎伴轻度低氧血症患者中的比较:一项随机对照试验

High-flow nasal oxygen versus conventional oxygen therapy in patients with COVID-19 pneumonia and mild hypoxaemia: a randomised controlled trial.
PubMed 文献 · Thorax · 2022-05-17

这项多中心随机对照试验纳入364例COVID-19肺炎伴轻度低氧血症(SpO2≤92%)需氧疗患者,比较经鼻高流量氧疗(HFNO)与常规氧疗(COT)对28天内呼吸支持升级的影响。结果显示两组呼吸支持升级率无显著差异(30.3% vs 38.6%,RR 0.79,95%CI 0.59-1.05,p=0.09),HFNO未能显著降低呼吸支持升级风险。

要点

  • COVID-19肺炎伴轻度低氧血症患者中,HFNO与COT的28天呼吸支持升级率无显著差异。
  • HFNO组呼吸支持升级率30.3%,COT组38.6%,绝对风险差-8.2%(95%CI -18%至+1.4%)。
  • 临床恢复、ICU入住率及住院时长在两组间均无显著差异。

核心结论

  • 在COVID-19肺炎伴轻度低氧血症患者中,使用HFNO并未显著降低28天内呼吸支持升级的可能性。

研究设计与样本

  • 多中心、随机、平行组、开放标签试验,纳入364例COVID-19肺炎伴外周血氧饱和度(SpO2)≤92%且需氧疗的患者,随机分为HFNO组(181例)和COT组(181例)。

主要发现

  • HFNO组55例(30.3%)与COT组70例(38.6%)在28天内发生呼吸支持升级,组间无显著差异(绝对风险差-8.2%,95%CI -18%至+1.4%;RR 0.79,95%CI 0.59-1.05;p=0.09)。
  • 临床恢复率HFNO组69.1% vs COT组60.8%,绝对风险差8.2%(95%CI -1.5%至+18.0%),RR 1.14(95%CI 0.98-1.32),无显著差异。
  • ICU入住率HFNO组7.7% vs COT组11.0%,绝对风险差-3.3%(95%CI -9.3%至+2.6%),无显著差异。
  • 住院时长HFNO组11天(IQR 8-17)vs COT组11天(IQR 7-20),绝对风险差-1.0%(95%CI -3.1%至+1.1%),无显著差异。

临床怎么用

  • 对于COVID-19肺炎伴轻度低氧血症需氧疗的患者,HFNO不应被视为优于COT以预防呼吸支持升级的常规策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: In patients with COVID-19 pneumonia and mild hypoxaemia, the clinical benefit of high-flow nasal oxygen (HFNO) remains unclear. We aimed to examine whether HFNO compared with conventional oxygen therapy (COT) could prevent escalation of respiratory support in this patient population. METHODS: In this multicentre, randomised, parallel-group, open-label trial, patients with COVID-19 pneumonia and peripheral oxygen saturation (SpO2) ≤92% who required oxygen therapy were randomised to HFNO or COT. The primary outcome was the rate of escalation of respiratory support (ie, continuous positive airway pressure, non-invasive ventilation or invasive mechanical ventilation) within 28 days. Among secondary outcomes, clinical recovery was defined as the improvement in oxygenation (SpO2 ≥96% with fractional inspired oxygen (FiO2) ≤30% or partial pressure of arterial carbon dioxide/FiO2 ratio >300 mm Hg). RESULTS: Among 364 randomised patients, 55 (30.3%) of 181 patients assigned to HFNO and 70 (38.6%) of 181 patients assigned to COT underwent escalation of respiratory support, with no significant difference between groups (absolute risk difference -8.2% (95% CI -18% to +1.4%); RR 0.79 (95% CI 0.59 to 1.05); p=0.09). There was no significant difference in clinical recovery (69.1% vs 60.8%; absolute risk difference 8.2% (95% CI -1.5% to +18.0%), RR 1.14 (95% CI 0.98 to 1.32)), intensive care unit admission (7.7% vs 11.0%, absolute risk difference -3.3% (95% CI -9.3% to +2.6%)), and in hospital length of stay (11 (IQR 8-17) vs 11 (IQR 7-20) days, absolute risk difference -1.0% (95% CI -3.1% to +1.1%)). CONCLUSIONS: Among patients with COVID-19 pneumonia and mild hypoxaemia, the use of HFNO did not significantly reduce the likelihood of escalation of respiratory support. TRIAL REGISTRATION NUMBER: NCT04655638.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Crimi C, Noto A, Madotto F, et al. High-flow nasal oxygen versus conventional oxygen therapy in patients with COVID-19 pneumonia and mild hypoxaemia: a randomised controlled trial. Thorax. 2022. PMID: 35580898. doi:10.1136/thoraxjnl-2022-218806

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。